Olga Millán

About me

Featured publications

• Monitoring of miR-181a-5p and miR-155-5p Plasmatic Expression as Prognostic Biomarkers for Acute and Subclinical Rejection in de novo Adult Liver Transplant Recipients

  Authors:

  Millan, Olga; Ruiz, Pablo; Orts, Lara; Ferre, Paula; Crespo, Gonzalo;

  Santana, Miguel; Fortuna, Virginia; Quintairos, Luis; Navasa, Miguel; Brunet, Merce;.

  Reference: Frontiers In Immunology 2019.

• Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report

  Authors:

  Brunet M; Van Gelder T; Åsberg A; Haufroid V; Hesselink D;

  (...)

  Sommerer C; Vethe N; De Winter B; Christians U; Bergan S.

  See complete list of authors

  Reference: Therapeutic Drug Monitoring 2019.

• Urinary miR-155-5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation.

  Authors:

  Millán O; Budde K; Sommerer C; Aliart I; Rissling O;

  (...)

  Matz M; Zeier M; Silva I; Guirado L; Brunet M .

  See complete list of authors

  Reference: British Journal Of Clinical Pharmacology 2017.

• Cytokine-based immune monitoring

  Authors:

  Millan, O.; Brunet, M.;;

  Reference: Clinical Biochemistry 2016.

• Barcelona consensus on biomarker-based immunosuppressive drugs management in solid organ transplantation

  Authors:

  Brunet M; Shipkova M; Van Gelder T; Wieland E; Sommerer C;

  (...)

  Hesselink D; Noceti O; Pawinski T; Wallemacq P; Oellerich M.

  See complete list of authors

  Reference: Therapeutic Drug Monitoring 2016.

• Flow cytometry as platform for biomarker discovery and clinical validation

  Authors:

  Millán O; Brunet M;

  Reference: 2015.

• Should IFN-γ, IL-17 and IL-2 be considered predictive biomarkers of acute rejection in liver and kidney transplant? Results of a multicentric study

  Authors:

  Millan, O; Rafael-Valdivia, L; San Segundo, D; Boix, F; Castro-Panete, MJ;

  (...)

  Miras, M; Andres, A; Guirado, L; Pascual, J; Brunet, M.

  See complete list of authors

  Reference: Clinical Immunology 2014.

• IFN-gamma, IL-17 and IL-2 as Predictive Biomarkers of Acute Rejection in Liver and Kidney Transplantation: Results of a Multicenter Study

  Authors:

  Millan, O; Rafael-Valdivia, L; San Segundo, D; Boix, F; Castro-Panete, M J;

  (...)

  Miras, M; Andres, A; Guirado, L; Pascual, J; Brunet, M.

  See complete list of authors

  Reference: Therapeutic Drug Monitoring 2013.

• Intracellular IFN-gamma and IL-2 expression monitoring as surrogate markers of the risk of acute rejection and personal drug response in de novo liver transplant recipients

  Authors:

  Millan, O; Rafael-Valdivia, L; Torrademe, E; Lopez, A; Fortuna, V;

  Sanchez-Cabus, S; Lopez-Pua, Y; Rimola, A; Brunet, M.

  Reference: Cytokine 2013.

• IFN-, IL-17 AND IL-2 AS PREDICTIVE BIOMARKERS OF ACUTE REJECTION IN LIVER AND KIDNEY TRANSPLANTATION: RESULTS OF A MULTICENTER STUDY

  Authors:

  Millan, Olga; Rafael-Valdivia, Lourdes; Segundo, David S; Boix, Fran; Castro-Panete, Maria J;

  (...)

  Miras, M; Andres, Amado; Guirado, Lluis; Pascual, Julio; Brunet, Merce.

  See complete list of authors

  Reference: Transplant International 2013.

Featured Projects

• Análisis de la expresión de un panel de miRNAs y Quimiocinas como biomarcadores pronóstico precoces del riesgo de rechazo mediado por células T y subclínico post-trasplante hepático

  Principal investigator: Merce Brunet Serra, Olga Millán López

  Funder: Instituto Carlos III (Ministerio de Educacion y Ciencia of Spain)  (Programa financiador competitivo)

  Code: PI19/00378

  Duration: 01/10/2019 - 31/10/2022

• miRNAs circulantes: Potenciales biomarcadores no invasivos de predicción de rechazo agudo en pacientes trasplantados hepáticos y renales

  Principal investigator: Olga Millán López

  Funder: Mutua Madrileña

  Duration: 01/09/2014 - 30/09/2017

• Evaluación del impacto de la aloreactividad en la evolución del injerto y de la reversibilidad de la fibrosis tras el tratamiento de la hepatitis C post-trasplante hepático

  Principal investigator: MIQUEL NAVASA ANADON, Merce Brunet Serra

  Funder: Instituto Carlos III (Ministerio de Educacion y Ciencia of Spain) 

  Duration: 01/09/2014 - 30/09/2017

• Estudio del efecto inmunomodulador de la Atorvastatina en trasplante renal: estudios in vitro e in vivo

  Principal investigator: Olga Millán López

  Funder: Mutua Madrileña

  Code: 08/247

  Duration: 01/09/2008 - 30/09/2011

• Estudio multicéntrico para la validación de los biomarcadores de elección que reflejan la respuesta individual de los pacientes trasplantados de órganos sólidos al tratamiento inmunosupresor.

  Principal investigator: Mercedes Brunet Serra

  Funder: Instituto de Salud Carlos III

  Code: PI080300

  Duration: 01/09/2008 - 30/09/2011